Kangbai Jia Bainga, Babawo Lawrence Sao, Kaitibi Daniel, Sandi Anthony A, George Angela Magdalene, Sahr Foday
Center for International Health, University of Munich (LMU), Munich, Germany.
Department of Environmental Health Sciences, Njala University, Freetown, Sierra Leone.
SN Compr Clin Med. 2021;3(1):11-15. doi: 10.1007/s42399-020-00704-3. Epub 2021 Jan 12.
October 11, 2020, marks the seventh month since the World Health Organization (WHO) officially declared COVID-19 a pandemic. Unlike other coronavirus diseases, there is a geographically disproportionate distribution of the incidence of COVID-19 cases around the world. We observed a significantly high COVID-19 cases and deaths in countries and territories with no or very small number of malaria cases or no or low national TB cases in 2018. We speculate that the high incidence of COVID-19 cases and deaths in countries less affected by malaria is partly due to overexposure to malaria which led to the regular use of the artemisinin anti-malaria drugs as well as the regular use of bacillus Calmette-Guérin (BCG) vaccine for TB prevention. The vaccine produced an almost life-long immunity to TB and meningitis to its recipients. We are thus calling for a COVID-19 containment and clinical management protocol that will incorporate the use of the anti-malaria ACT drug cocktail and BCG vaccine on compassionate ground.
2020年10月11日，是世界卫生组织（WHO）正式宣布新冠疫情为大流行的第七个月。与其他冠状病毒疾病不同，全球新冠肺炎病例的发病率在地理分布上并不均衡。我们观察到，在2018年疟疾病例数极少或没有、或国家结核病病例数极少或没有的国家和地区，新冠肺炎病例和死亡人数显著偏高。我们推测，受疟疾影响较小的国家中新冠肺炎病例和死亡人数居高不下，部分原因是过度接触疟疾，导致人们经常使用青蒿素抗疟药物，以及经常使用卡介苗（BCG）预防结核病。这种疫苗为接种者提供了几乎终身的结核病和脑膜炎免疫力。因此，我们呼吁制定一项新冠疫情防控和临床管理方案，在人道主义基础上纳入使用抗疟ACT药物组合和卡介苗。
